Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140469 | Lung Cancer | 2016 | 7 Pages |
Abstract
Most lung cancer physicians manage inoperable stage II NSCLC patients with curative intent, but consensus on how to optimally employ radiotherapy and/or chemotherapy is lacking. Future prospective, randomized trials are warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Shaan Dudani, Natasha B. Leighl, Cheryl Ho, Jason R. Pantarotto, Xiaofu Zhu, Tinghua Zhang, Paul Wheatley-Price,